Conjoint Associate Professor Jarad Martin
Conjoint Associate Professor
School of Medicine and Public Health
Conjoint Associate Professor Jarad Martin (DMEd, FRANZCR, GAustMS, MB ChB, BSc) is the Director of Research (Department of Radiation Oncology) and Radiation Oncologist at the Calvary Mater Newcastle, and Visiting Medical Officer at Genesis Cancer Care, Lake Macquarie Private Hospital.
With strong research interests in the areas of gastrointestinal and genitourinary oncology, A/Prof Martin has attracted over $6.5 million in competitive grant funding and has over 60 peer-reviewed publications to date. He is also Senior author on the Australasian guidelines for prostate cancer radiotherapy.
A/Prof Martin's professional leadership roles include: Faculty of Radiation Oncology; Chairperson Research Committee, Faculty of Radiation Oncology, Royal Australian and New Zealand College of Radiologists; Australia New Zealand Urological and Prostate Cancer Trials Group Scientific Advisory Committee; Trans-Tasman Radiation Oncology Group (TROG) Clinical Liason Leader; and Deputy Chairperson, Hunter Cancer Research Alliance (HCRA) Implementation Science Flagship Committee.
- Doctor of Medicine, University of Queensland
- Bladder Cancer
- Gastrointestinal Cancer
- Magnetic Resonance Imaging
- Oesophageal Cancer
- Prostate Cancer
- Radiation Oncology
- Rectal Cancer
- Stereotactic Body Radiotherapy
- Therapy and Treatment
- English (Mother)
Fields of Research
|Dates||Title||Organisation / Department|
Visiting Radiation Oncologist
A/Prof Martin is engaged with Australia's largest provider of radiotherapy services with over 25 campuses.
|Genesis Cancer Care, Lake Macquarie Private Hospital
Director of Research (Department of Radiation Oncology), Radiation Oncologist
A/Prof Martin is a clinician who also helps shape research strategy within the field of Radiation Oncology.
|Calvary Mater Newcastle
|30/04/2007 - 30/04/2012||Radiation Oncologist||Radiation Oncology Queensland, Toowoomba, Queensland
|1/07/2006 - 27/04/2007||Locum Radiation Oncologist||Royal Brisbane and Women's Hospital
|1/07/2005 - 30/06/2006||
Fellow in Radiation Oncology
A/Prof Martin did his advanced fellowship training at the Princess Margaret Hospital, one of the world's largest and most respected radiotherapy centres.
|University of Toronto
|23/07/2001 - 30/06/2005||
Registrar in Radiation Oncology
A/Prof Martin did his clinical training at the Peter Mac - Australia's largest cancer hospital.
|Peter MacCallum Cancer Centre
For publications that are currently unpublished or in-press, details are shown in italics.
Chapter (1 outputs)
Fay MF, Martin JM, Porceddu SV, O'Sullivan B, 'Acute and Late Radiation Therapy Effects', When Cancer Crosses Disciplines, World Scientific, London 179-200 (2009)
Journal article (59 outputs)
Forshaw K, Hall AE, Boyes AW, Carey ML, Martin J, 'Patients' Experiences of Preparation for Radiation Therapy: A Qualitative Study.', Oncol Nurs Forum, 44 E1-E9 (2017)
Supiot S, Delaroche G, Latorzeff I, Magne N, CrÃ©hange G, Carrie C, et al., 'Profit (Prostate Fractionated Irradiation Trial)Â¿: rÃ©sultats dÂ¿une Ã©tude internationale randomisÃ©e comparant deux schÃ©mas dÂ¿irradiation des cancers de prostate de risque intermÃ©diaire.', Prog Urol, 26 793-794 (2016)
Chandra SS, Dowling JA, Greer PB, Martin J, Wratten C, Pichler P, et al., 'Fast automated segmentation of multiple objects via spatially weighted shape learning', PHYSICS IN MEDICINE AND BIOLOGY, 61 8070-8084 (2016)
Martin J, Arm J, Smart J, Palazzi K, Capp A, Ainsworth P, Cowin G, 'Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity', European Radiology, 1-9 (2016)
Â© 2016 European Society of RadiologyObjectives: To explore changes in bone mineral density (BMD) measured by DEXA and MRS fat fraction (FF), Dixon FF, and ADC in lower spinal ver... [more]
Â© 2016 European Society of RadiologyObjectives: To explore changes in bone mineral density (BMD) measured by DEXA and MRS fat fraction (FF), Dixon FF, and ADC in lower spinal vertebral bodies in men with prostate cancer treated with androgen deprivation therapy (ADT). Methods: Twenty-eight men were enrolled onto a clinical trial. All received ADT. DEXA imaging was performed at baseline and 12 months. L-spine MRI was done at baseline and 6 months. Results: The number of patients who underwent DEXA, Dixon, ADC, and MRS at baseline/follow-up were 28/27, 28/26, 28/26, and 22/20. An increase in FF was observed from T11 to S2 (average 1 %/vertebra). There was a positive correlation between baseline MRS FF and Dixon FF (r = 0.85, p < 0.0001) and a negative correlation between MRS FF and ADC (r = -0.56, p = 0.036). Over 6 months, MRS FF increased by a median of 25 % in relative values (p = 0.0003), Dixon FF increased (p < 0.0001) and ADC values decreased (p = 0.0014). Men with >5 % BMD loss after 1 year had triple the percentage increase in MRS FF at 6 months (61.1 % vs. 20.9 %, p = 0.19). Conclusions: Changes are observed on L-spine MRI after 6 months of ADT. Further investigation is warranted of MRS change as a potential predictive biomarker for later BMD loss. Key Points: Â¿ Spinal marrow fat fraction increases after 6 months of androgen deprivation therapy.Â¿ More inferior vertebral bodies tend to have higher fat fractions.Â¿ MRS fat fraction changes were associated with later changes in DEXA BMD.
Schmidt C, Martin JM, Khoo E, Plank A, Grigg R, 'Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center', HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 37 1808-1815 (2015) [C1]
Loh J, Baker K, Sridharan S, Greer P, Wratten C, Capp A, et al., 'Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?', RADIATION ONCOLOGY, 10 (2015) [C1]
Dowling JA, Sun J, Pichler P, Rivest-HÃ©nault D, Ghose S, Richardson H, et al., 'Automatic substitute computed tomography generation and contouring for magnetic resonance imaging (MRI)-alone external beam radiation therapy from standard MRI sequences', International Journal of Radiation Oncology Biology Physics, 93 1144-1153 (2015) [C1]
Crown Copyright Â© 2015 Published by Elsevier Inc. All rights reserved.Purpose To validate automatic substitute computed tomography CT (sCT) scans generated from standard T2-weigh... [more]
Crown Copyright Â© 2015 Published by Elsevier Inc. All rights reserved.Purpose To validate automatic substitute computed tomography CT (sCT) scans generated from standard T2-weighted (T2w) magnetic resonance (MR) pelvic scans for MR-Sim prostate treatment planning. Patients and Methods A Siemens Skyra 3T MR imaging (MRI) scanner with laser bridge, flat couch, and pelvic coil mounts was used to scan 39 patients scheduled for external beam radiation therapy for localized prostate cancer. For sCT generation a whole-pelvis MRI scan (1.6 mm 3-dimensional isotropic T2w SPACE [Sampling Perfection with Application optimized Contrasts using different flip angle Evolution] sequence) was acquired. Three additional small field of view scans were acquired: T2w, T2*w, and T1w flip angle 80Â° for gold fiducials. Patients received a routine planning CT scan. Manual contouring of the prostate, rectum, bladder, and bones was performed independently on the CT and MR scans. Three experienced observers contoured each organ on MRI, allowing interobserver quantification. To generate a training database, each patient CT scan was coregistered to their whole-pelvis T2w using symmetric rigid registration and structure-guided deformable registration. A new multi-atlas local weighted voting method was used to generate automatic contours and sCT results. Results The mean error in Hounsfield units between the sCT and corresponding patient CT (within the body contour) was 0.6 Â± 14.7 (mean Â± 1 SD), with a mean absolute error of 40.5 Â± 8.2 Hounsfield units. Automatic contouring results were very close to the expert interobserver level (Dice similarity coefficient): prostate 0.80 Â± 0.08, bladder 0.86 Â± 0.12, rectum 0.84 Â± 0.06, bones 0.91 Â± 0.03, and body 1.00 Â± 0.003. The change in monitor units between the sCT-based plans relative to the gold standard CT plan for the same dose prescription was found to be 0.3% Â± 0.8%. The 3-dimensional Â¿ pass rate was 1.00 Â± 0.00 (2 mm/2%). Conclusions The MR-Sim setup and automatic sCT generation methods using standard MR sequences generates realistic contours and electron densities for prostate cancer radiation therapy dose planning and digitally reconstructed radiograph generation.
Trada Y, Kneebone A, Paneghel A, Pearse M, Sidhom M, Tang C, et al., 'Optimizing radiation therapy quality assurance in clinical trials: A TROG 08.03 RAVES substudy', International Journal of Radiation Oncology Biology Physics, 93 1045-1051 (2015) [C1]
Crown Copyright Â© 2015 Published by Elsevier Inc. All rights reserved.Purpose To explore site- and clinician-level factors associated with protocol violations requiring real-time... [more]
Crown Copyright Â© 2015 Published by Elsevier Inc. All rights reserved.Purpose To explore site- and clinician-level factors associated with protocol violations requiring real-time-review (RTR) resubmission in a multicenter clinical trial to help tailor future quality assurance (QA) protocols. Methods and Materials RAVES (Radiation Therapy-Adjuvant vs Early Salvage) (Trans-Tasman Radiation Oncology Group 08.03) is a randomized trial comparing adjuvant with early salvage radiation therapy in men with positive surgical margins or pT3 disease after prostatectomy. Quality assurance in RAVES required each clinician and site to submit a credentialing dummy run (DR) and for each patient's radiation therapy plan to undergo external RTR before treatment. Prospectively defined major violations from trial protocol required remedy and resubmission. Site and clinician factors associated with RTR resubmission were examined using hierarchical modeling. Results Data were collected from 171 consecutive patients, treated by 46 clinicians at 32 hospitals. There were 47 RTR resubmissions (27%) due to 65 major violations. The relative rate of resubmission decreased by 29% per year as the study progressed (odds ratio OR. 0.71, P=.02). The majority of resubmissions were due to contouring violations (39 of 65) and dosimetric violations (22 of 65). For each additional patient accrued, significant decreases in RTR resubmission were seen at both clinician level (OR 0.75, P=.02) and site level (OR 0.72, P=.01). The rate of resubmission due to dosimetric violations was only 1.6% after the first 5 patients. Use of IMRT was associated with lower rates of resubmission compared with 3-dimensional conformal radiation therapy (OR 0.38, P=.05). Conclusion Several low- and high-risk factors that may assist with tailoring future clinical trial QA were identified. Because the real-time resubmission rate was largely independent of the credentialing exercise, some form of RTR QA is recommended. The greatest benefit from QA was derived early in trial activation and clinician experience.
Jones M, Hruby G, Stanwell P, Gallagher S, Wong K, Arm J, Martin J, 'Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy.', BMC Cancer, 15 281 (2015) [C3]
Sun J, Dowling JA, Pichler P, Parker J, Martin J, Stanwell P, et al., 'Investigation on the performance of dedicated radiotherapy positioning devices for MR scanning for prostate planning', Journal of Applied Clinical Medical Physics, 16 4-13 (2015) [C1]
The purpose of this study was to investigate performance of the couch and coil mounts designed for MR-simulation prostate scanning using data from ten volunteers. Volunteers were ... [more]
The purpose of this study was to investigate performance of the couch and coil mounts designed for MR-simulation prostate scanning using data from ten volunteers. Volunteers were scanned using the standard MR scanning protocol with the MR coil directly strapped on the external body and the volunteer lying on the original scanner table. They also were scanned using a MR-simulation table top and pelvic coil mounts. MR images from both setups were compared in terms of body contour variation and image quality effects within particular organs of interest. Six-field conformal plans were generated on the two images with assigned bulk density for dose calculation. With the MR-simulation devices, the anterior skin deformation was reduced by up to 1.7 cm. The hard tabletop minimizes the posterior body deformation which can be up to 2.3 cm on the standard table, depending on the weight of volunteer. The image signal-to-noise ratio reduced by 14% and 25% on large field of view (FOV) and small FOV images, respectively, after using the coil mount; the prostate volume contoured on two images showed difference of 1.05 Â± 0.66 cm3. The external body deformation caused a mean dose reduction of 0.6 Â± 0.3 Gy, while the coverage reduced by 22% Â± 13% and 27% Â± 6% in V
Sun J, Dowling J, Pichler P, Menk F, Rivest-Henault D, Lambert J, et al., 'MRI simulation: End-to-end testing for prostate radiation therapy using geometric pelvic MRI phantoms', Physics in Medicine and Biology, 60 3097-3109 (2015) [C1]
Â© 2015 Institute of Physics and Engineering in Medicine.To clinically implement MRI simulation or MRI-alone treatment planning requires comprehensive end-to-end testing to ensure... [more]
Â© 2015 Institute of Physics and Engineering in Medicine.To clinically implement MRI simulation or MRI-alone treatment planning requires comprehensive end-to-end testing to ensure an accurate process. The purpose of this study was to design and build a geometric phantom simulating a human male pelvis that is suitable for both CT and MRI scanning and use it to test geometric and dosimetric aspects of MRI simulation including treatment planning and digitally reconstructed radiograph (DRR) generation. A liquid filled pelvic shaped phantom with simulated pelvic organs was scanned in a 3T MRI simulator with dedicated radiotherapy couch-top, laser bridge and pelvic coil mounts. A second phantom with the same external shape but with an internal distortion grid was used to quantify the distortion of the MR image. Both phantoms were also CT scanned as the gold-standard for both geometry and dosimetry. Deformable image registration was used to quantify the MR distortion. Dose comparison was made using a seven-field IMRT plan developed on the CT scan with the fluences copied to the MR image and recalculated using bulk electron densities. Without correction the maximum distortion of the MR compared with the CT scan was 7.5 mm across the pelvis, while this was reduced to 2.6 and 1.7 mm by the vendor's 2D and 3D correction algorithms, respectively. Within the locations of the internal organs of interest, the distortion was <1.5 and <1 mm with 2D and 3D correction algorithms, respectively. The dose at the prostate isocentre calculated on CT and MRI images differed by 0.01% (1.1 cGy). Positioning shifts were within 1 mm when setup was performed using MRI generated DRRs compared to setup using CT DRRs. The MRI pelvic phantom allows end-to-end testing of the MRI simulation workflow with comparison to the gold-standard CT based process. MRI simulation was found to be geometrically accurate with organ dimensions, dose distributions and DRR based setup within acceptable limits compared to CT.
Wu R, Woodford H, Capp A, Hunter P, Cowin G, Tai KH, et al., 'A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes', Radiation Oncology, 10 (2015) [C1]
Â© 2015 Wu et al.Background: A prospective clinical trial was conducted to evaluate the feasibility of a novel approach to the treatment of patients with high risk prostate cancer... [more]
Â© 2015 Wu et al.Background: A prospective clinical trial was conducted to evaluate the feasibility of a novel approach to the treatment of patients with high risk prostate cancer (HRPC) through the use of a nomogram to tailor radiotherapy target volumes. Methods: Twenty seven subjects with HRPC were treated with a mildly hypofractionated radiotherapy regimen using image-guided IMRT technique between Jun/2013-Jan/2015. A set of validated prognostic factors were inputted into the Memorial-Sloan-Kettering Cancer Center (MSKCC) prostate cancer nomogram to estimate risk of loco-regional spread (LRS). The nomogram risk estimates for extra-capsular extension (ECE), seminal vesicles involvement (SVI), and pelvic lymph nodes involvement (LNI) were used to adapt radiotherapy treatment volumes based on a risk threshold of =15% in all cases. A planning guide was used to delineate target volumes and organs at risk (OAR). Up to three dose levels were administered over 28 fractions; 70Gy for gross disease in the prostate +/- seminal vesicles (2.5Gy/fraction), 61.6Gy for subclinical peri-prostatic disease (2.2Gy/fraction) and 50.4Gy to pelvic nodes (1.8Gy/fraction). Data regarding protocol adherence, nomogram use, radiotherapy dose distribution, and acute toxicity were collected. Results: Nomogram use 100% of patients were treated for ECE, 88.9% for SVI, and 70.4% for LNI. The three areas at risk of LRS were appropriately treated according to the study protocol in 98.8% cases. The MSKCC nomogram estimates for LRS differed significantly between the time of recruitment and analysis. Contouring protocol compliance Compliance with the trial contouring protocol for up to seven target volumes was 93.0% (159/171). Compliance with protocol for small bowel contouring was poor (59.3%). Dose constraints compliance Compliance with dose constraints for target volumes was 97.4% (191/196). Compliance with dose constraints for OAR was 88.2% (285/323). Acute toxicity There were no grade 3 acute toxicities observed. 20/27 (74.1%) and 6/27 (22.2%) patients experienced a grade 2 genitourinary and gastrointestinal toxicity respectively. Conclusions: We have demonstrated the feasibility of this novel risk-adapted radiation treatment protocol for HRPC. This study has identified key learning points regarding this approach, including the importance of standardization and updating of risk quantification tools, and the utility of an observer to verify their correct use. Trial registration: ClincialTrials.gov identifier NCT01418040. Hunter New England Human Research Ethics Committee (HNEHREC) reference number 12/08/15/4.02
Jones M, Hruby G, Solomon M, Rutherford N, Martin J, 'The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis', ANNALS OF SURGICAL ONCOLOGY, 22 3574-3581 (2015) [C1]
Loh J, Jovanovic L, Lehman M, Capp A, Pryor D, Harris M, et al., 'Circulating tumor cell detection in high-risk non-metastatic prostate cancer', Journal of Cancer Research and Clinical Oncology, 140 2157-2162 (2014) [C1]
Â© 2014, Springer-Verlag Berlin Heidelberg.Results: The median age was 70Â¿years, median PSA was 14.1, and the median Gleason score was 9. The median 5-year risk of progression of... [more]
Â© 2014, Springer-Verlag Berlin Heidelberg.Results: The median age was 70Â¿years, median PSA was 14.1, and the median Gleason score was 9. The median 5-year risk of progression of disease using a validated nomogram was 39Â¿%. Five out of 36 patients (14Â¿%, 95Â¿% CI 5Â¿30Â¿%) had CTCs detected in their circulation. Four patients had only 1 CTC per 7.5Â¿mL of blood detected. One patient had 3 CTCs per 7.5Â¿mL of blood detected, which included a circulating tumor microemboli. Both on univariate analysis and multivariate analysis, there were no correlations found between CTC positivity and the classic prognostic factors including PSA, Gleason score, T-stage and age.Conclusion: This study demonstrates that patients with high-risk, non-metastatic prostate cancer present infrequently with small number of CTCs in peripheral blood. This finding is consistent with the limited literature available in this setting. Other CTC isolation and detection technologies with improved sensitivity and specificity may enable detection of CTCs with mesenchymal phenotypes, although none as yet have been validated for clinical use. Newer assays are emerging for detection of new putative biomarkers for prostate cancer. Correlation of disease control outcomes with CTC detection will be important.Purpose: The detection of circulating tumor cells (CTCs) provides important prognostic information in men with metastatic prostate cancer. We aim to determine the rate of detection of CTCs in patients with high-risk non-metastatic prostate cancer using the CellSearchÂ® method.Method: Samples of peripheral blood (7.5Â¿mL) were drawn from 36 men with newly diagnosed high-risk non-metastatic prostate cancer, prior to any initiation of therapy and analyzed for CTCs using the CellSearchÂ® method.
Lehman M, Sidhom M, Kneebone AB, Hayden AJ, Martin JM, Christie D, et al., 'FROGG high-risk prostate cancer workshop: Patterns of practice and literature review. Part II post-radical prostatectomy', Journal of Medical Imaging and Radiation Oncology, 58 392-400 (2014) [C1]
Australian and New Zealand radiation oncologists with an interest in uro-oncology were invited to undertake a pattern of practice survey dealing with issues encountered in the man... [more]
Australian and New Zealand radiation oncologists with an interest in uro-oncology were invited to undertake a pattern of practice survey dealing with issues encountered in the management of high-risk prostate cancer in the post-prostatectomy setting. Responses from practitioners revealed a lack of consensus regarding the optimal timing of radiation therapy the use of whole pelvic radiation therapy and the use of androgen deprivation therapy. A review of the literature outlining the current body of knowledge and the clinical studies that will inform future practice is presented. Â© 2013 The Royal Australian and New Zealand College of Radiologists.
Loh J, Davis ID, Martin JM, Siva S, 'Extracranial oligometastatic renal cell carcinoma: current management and future directions', FUTURE ONCOLOGY, 10 761-774 (2014) [C1]
Ratnayake G, Martin J, Plank A, Wong W, 'Incremental changes verses a technological quantum leap: The additional value of intensity-modulated radiotherapy beyond image-guided radiotherapy for prostate irradiation', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 58 503-510 (2014) [C1]
Robson K, Alizart M, Martin J, Nagel R, 'Coeliac Patients Are Undiagnosed at Routine Upper Endoscopy', PLOS ONE, 9 (2014) [C1]
Lehman M, Hayden AJ, Martin JM, Christie D, Kneebone AB, Sidhom M, et al., 'FROGG high-risk prostate cancer workshop: Patterns of practice and literature review: Part I: Intact prostate', Journal of Medical Imaging and Radiation Oncology, 58 257-265 (2014) [C1]
Australian and New Zealand radiation oncologists with an interest in uro-oncology were invited to participate in a pattern-of-practice survey dealing with the management of intact... [more]
Australian and New Zealand radiation oncologists with an interest in uro-oncology were invited to participate in a pattern-of-practice survey dealing with the management of intact high-risk prostate cancer. Responses from 46 practitioners (representing 73% of all potential respondents) revealed that high-dose radiation therapy is the standard of care. However, there is variability in practice with regard to the methods used to achieve dose escalation, the use of whole-pelvic radiation therapy and the optimal duration of androgen deprivation therapy employed. A review of the literature outlining the current body of knowledge and the planned and ongoing studies in intact high-risk prostate cancer is presented. Â© 2013 The Authors. Journal of Medical Imaging and Radiation Oncology published by Wiley Publishing Asia Pty Ltd on behalf of Royal Australian and New Zealand College of Radiologists.
Izard MA, Morris LM, Wan W-Y, Martin J, 'Long-term outcome for prostate cancer using pseudo pulse-dosed rate brachytherapy, external beam radiotherapy, and hormones', BRACHYTHERAPY, 12 608-614 (2013) [C1]
Grimison P, Houghton B, Chatfield M, Toner GC, Davis ID, Martin J, et al., 'Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage i testicular cancer', BJU International, 112 (2013) [C1]
|Show 56 more journal articles|
Conference (6 outputs)
|2016||Mian M, Kumar M, Wills V, Johnson C, Skov A, Wright T, et al., 'TRANSLATION OF THE CROSS TRI-MODALITY PROTOCOL FOR ESOPHAGEAL CANCER TO THE GENERAL POPULATION: A COMPLIANCE AUDIT', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)|
|2011||Trada Y, Plank A, Martin JM, 'Establishing a Dose Response Relationship for the Treatment of Prostate Cancer With External Beam Radiotherapy: a Meta-analysis', EUROPEAN JOURNAL OF CANCER (2011) [E3]|
Jackson JE, Dickie GJ, Wiltshire KL, Keller J, Tripcony L, Poulsen MG, et al., 'RADIOTHERAPY FOR PERINEURAL INVASION IN CUTANEOUS HEAD AND NECK CARCINOMAS: TOWARD A RISK-ADAPTED TREATMENT APPROACH', HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2009) [E1]
|Show 3 more conferences|
Thesis / Dissertation (1 outputs)
Martin JM, Imaging and Radiotherapy in Prostate Cancer: Advances in Biomarkers and Treatment, University of Queensland (2016)
Number of supervisions
Total current UON EFTSL
|Commenced||Level of Study||Research Title / Program / Supervisor Type|
In Vivo Dosimetry and Intrafraction Motion During Prostate Radiotherapy
PhD (Physics), Faculty of Science, The University of Newcastle
Anal Cancer and Multiparametric MRI
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Radiotherapy and Cancer: Integration of Biology and Technology
Radiation Oncology is a rapidly changing field with a vital role to play in the management of the modern cancer patient. With the golden age of basic sciences and availability of new imaging and treatment approaches, there are hugh opportunities to explore. Our centre is willing to discuss research interests of prospective students and to help tailor a higher research degree to their talents and clinical need.
Priority Research Centre for Cancer Research, Innovation and Translation
30/10/2016 - 31/12/2020
Doctor Mary-Claire Hanlon
The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.
|Country||Count of Publications|